Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (iparomlimab + tuvonralimab) plus gemcitabine in advanced driver gene-negative squamous NSCLC after PD-(L)1 inhibitor therapy
ChiCTR2600120009Phase 2Not yet recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600120009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120009.